SAB Biotherapeutics CMO reports RSU tax withholding transaction

SAB Biotherapeutics, Inc. reported an insider equity transaction by its Chief Medical Officer, Alexandra Kropotova.

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. reported an insider equity transaction by its Chief Medical Officer, Alexandra Kropotova. On 12/11/2025, 988 shares of common stock were withheld to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs).

After this transaction, Kropotova beneficially owned a total of 44,284 shares of common stock. This amount includes 31,946 shares of common stock and 12,338 shares that remain subject to vesting of RSUs granted under the company’s 2021 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 988 shares

Exercise Price or Tax Liability 1 txn

Insider Kropotova Alexandra

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	988	$0.00	$0.00

Holdings After Transaction: Common Stock — 44,284 shares (Direct)

Footnotes (3)

1. F1. Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").
2. F2. Includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.
3. F3. Each RSU represents a contingent right to receive one share of Common Stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SAB Biotherapeutics (SABS) disclose in this filing?

The filing shows that Chief Medical Officer Alexandra Kropotova had 988 shares of common stock withheld on 12/11/2025 to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).

How many SAB Biotherapeutics (SABS) shares does Alexandra Kropotova own after the transaction?

Following the reported transaction, Alexandra Kropotova beneficially owns 44,284 shares of SAB Biotherapeutics common stock.

How is the 44,284-share holding of SAB Biotherapeutics (SABS) broken down?

The 44,284 shares beneficially owned include 31,946 shares of common stock and 12,338 shares that remain subject to vesting of RSUs granted under the 2021 Equity Incentive Plan, as amended.

Why were 988 SAB Biotherapeutics (SABS) shares withheld in this Form 4?

The 988 shares of SAB Biotherapeutics common stock were withheld to satisfy tax withholding requirements upon the vesting of the company’s restricted stock units held by Alexandra Kropotova.

What does each SAB Biotherapeutics (SABS) RSU represent for Alexandra Kropotova?

Each RSU held by Alexandra Kropotova represents a contingent right to receive one share of SAB Biotherapeutics common stock, subject to vesting conditions.

What is Alexandra Kropotova’s role at SAB Biotherapeutics (SABS)?

In this filing, Alexandra Kropotova is identified as an officer of SAB Biotherapeutics, serving as the company’s Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/12/2025 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kropotova Alexandra

(Last) (First) (Middle)

777 W 41ST

SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		F		988(1)	D	(1)	44,284(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

2. Includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

3. Each RSU represents a contingent right to receive one share of Common Stock.

	Alexandra Kropotova	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.